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Supplementary Figure 1 
Binding profiles of key transcription factors to the Bcl11b gene and enhancer. 
A)-C) UCSC genome browser tracks (mm9 coordinates) showing published ChIP-Seq binding data of the 
following transcription factors to the Bcl11b gene: Notch11, CSL1, Gata32, PU.12, TCF-13, Runx14 (both WT and 
Runx1-/- control) and Ikaros5.  The H3K4me2 histone mark is also included2. The primary cell types on which 
ChIP-Seq was performed are also indicated.  A) Global view of Bcl11b locus, showing gene body in relation to 
distal enhancer and downstream gene desert.  Shaded yellow bars indicate gene and enhancer locations.  B) 
Bcl11b gene body, and C) Bcl11b enhancer domain.  Gray shaded bars indicate regions containing clusters of 
transcription factor binding sites and H3K4me marks.  Asterisk indicates binding sites tested in enhancer 
transfection assays6.  Note that a high resolution version of this figure is also provided separately. 
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Supplementary Figure 2 
Generation and validation of Bcl11b-YFP knock-in reporter. 
A) Schematic showing targeted insertion of fluorescent protein reporter into 3’-untranslated region (UTR) of 
Bcl11b locus (top), along with excision of the loxP-flanked PGK-neomycin cassette using Cre recombinase.  Cut 
sites for restriction enzymes PacI, CspCI, used for Southern Blot validation of targeted insertion in B) are 
shown.  Diagram is not drawn to scale.  B) Correct insertion of fluorescent protein cassette was validated by 
Southern Blot analysis on the targeted ES cell clone (left), which was later used for knock-in mouse generation. 
Bacterial Artificial Chromosomes (BAC) containing either the wildtype Bcl11b locus (center), or a Bcl11bYFP 
(+neo) locus (right) were used as controls.  
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Supplementary Figure 3 
Bcl11b-YFP levels are not affected by presence of the neomycin drug resistance cassette.   
Flow cytometry analysis of Bcl11bYFP/+ mice either with or without the neomycin drug selection cassette 
[Bcl11b-YFP(+neo), Bcl11b-YFP(-neo)], together with non-fluorescent controls (B6), using cells from the whole 
thymus (A), DN thymus (B), or the spleen (C). Bcl11b-YFP reporter expression is identical with or without the 
drug resistance cassette.  ISP – immature single positive, DP – double positive. 
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Supplementary Figure 4 
Experimental and analysis workflow for time-lapse imaging of Bcl11b-YFP levels in progenitor cells. 
A) Experimental setup, microscope configuration and illumination settings used for timelapse image 
acquisition.  To confine cells to a single imaging field-of-view, progenitors were seeded into hollow PDMS 
microwells (Microsurfaces; Flemington, Australia) adhered to a glass-bottomed 24 well dish (Mattek; Ashland, 
MA).  B) Workflow for image analysis showing (I) raw differential interference contrast (DIC), mCherry and YFP 
images; (II) representative images overlaid with automatically segmented cell boundaries; and (III) heat maps 
showing cytometric analysis of segmented cells, showing OFF and ON populations. 
 
Nature Immunology: doi:10.1038/ni.3514
 
 
 
Supplementary Figure 5 
Notch signaling promotes all-or-none Bcl11b activation in a dose-dependent manner. 
Flow cytometry analysis of bone marrow derived Bcl11b-YFP- DN2 cells cultured under the indicated 
conditions with 5 ng/mL IL-7 and Flt3L for four days. CD25 versus Bcl11b-YFP levels (top), and histograms of 
Bcl11b-YFP and CellTrace Violet levels (bottom) are shown.  Initial levels (Day 0) are shown as gray dotted 
lines.  GSI: γ-secretase inhibitor (Calbiochem/EMD Millipore, Billerica, MA), a small molecule inhibitor of Notch 
signaling. 
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Supplementary Figure 6 
shTcf7 constructs reduce Tcf7 transcript levels in ETP and DN2 cells. 
Quantitative real time (RT)-PCR analysis of Tcf7 transcript levels in DN progenitors from E14.5 fetal livers 
infected with the indicated shRNA constructs for 2 days and sorted.  RNA was extracted and processed as 
previously described7.   Forward and reverse primers used for Tcf7 detection are 
CAAGGCAGAGAAGGAGGCTAAG and GGCAGCGCTCTCCTTGAG respectively, as previously described8. 
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Supplementary Figure 7 
Effects of TCF-1 perturbation on Bcl11b activation in pro-T cells. 
A) Flow cytometry analysis of bone marrow DN progenitors transduced with either shRNA to Tcf7 (shTcf7) or a 
non-targeting control (shRandom), then cultured on plates coated with 6 µg/mL DL1 with 5 ng/mL SCF, IL-7 
and Flt3L for four days.  Levels of the dendritic cell marker CD11c against FSC (top), as well as CD25 levels 
versus Bcl11b-YFP levels (middle) or Bcl11b-YFP level distributions (bottom) for CD11c- populations are shown.  
Knockdown of Tcf7 promotes DC trans-differentiation in DN2 cells, but does not impede Bcl11b activation.  B) 
Flow cytometry analysis of Bcl11b-YFP expression levels in bone marrow DN progenitors transduced with a 
control or VEX-GFP retroviral construct for over-expression of TCF-1 (encoded by Tcf7), and cultured on OP9- 
or OP9-DL1 monolayers in 5 ng/mL IL-7 and Flt3L for three days.  TCF-1 over-expression does not affect Bcl11b 
activation from either ETP or DN2 progenitors. 
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Supplementary Figure 8 
Runx1, but not TCF-1 or GATA-3, controls Bcl11b expression amplitude in mature T cells. 
A) Published transcriptomic data on Bcl11b expression in wildtype or Tcf7-/- DN3 thymocytes9 (left), or in 
wildtype or Gata3-/- Th2 cells10 (right).  Levels of Bcl11b expression are similar in the absence or presence of 
either factor. B) Flow cytometry analysis of CD4 and CD8 splenic T-cells activated with anti-TCRβ and anti-
CD28 for 1 day, transduced with shRNA constructs, and cultured for 3 days.  Plots show CD8 versus CD3 for 
cells transduced with retrovirus (top), along with Bcl11b level distributions for gated non-CD8 T-cell 
populations (bottom).  Corresponding data for CD8 T-cells are shown in Fig. 8.  Solid black lines indicate cells 
transduced with random shRNA, and dotted lines indicate background levels from non-fluorescent T-cells.  
Data from (A) represent mean and S.D. of two independent experiments.    
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Supplementary Fig. 1:  Binding profiles of key transcription factors to the Bcl11b gene and 
enhancer. A)-C) UCSC genome browser tracks (mm9 coordinates) showing published ChIP-Seq 
binding data of the following transcription factors to the Bcl11b gene: Notch11, CSL1, Gata32, 
PU.12, TCF-13, Runx14 (both WT and Runx1-/- control) and Ikaros5.  The H3K4me2 histone mark 
is also included2. The primary cell types on which ChIP-Seq was performed are also indicated.  
A) Global view of Bcl11b locus, showing gene body in relation to distal enhancer and 
downstream gene desert.  Shaded yellow bars indicate gene and enhancer locations.  B) Bcl11b 
gene body, and C) Bcl11b enhancer domain.  Gray shaded bars indicate regions containing 
clusters of transcription factor binding sites and H3K4me marks.  Asterisk indicates binding sites 
tested in enhancer transfection assays6.  Note that a high resolution version of this figure is also 
provided separately. 
 
Supplementary Fig. 2: Generation and validation of Bcl11b-YFP knock-in reporter.  A) 
Schematic showing targeted insertion of fluorescent protein reporter into 3’-untranslated 
region (UTR) of Bcl11b locus (top), along with excision of the loxP-flanked PGK-neomycin 
cassette using Cre recombinase.  Cut sites for restriction enzymes PacI, CspCI, used for Southern 
Blot validation of targeted insertion in B) are shown.  Diagram is not drawn to scale.  B) Correct 
insertion of fluorescent protein cassette was validated by Southern Blot analysis on the 
targeted ES cell clone (left), which was later used for knock-in mouse generation. Bacterial 
Artificial Chromosomes (BAC) containing either the wildtype Bcl11b locus (center), or a 
Bcl11bYFP (+neo) locus (right) were used as controls. 
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Supplementary Fig. 3: Bcl11b-YFP levels are not affected by presence of the neomycin drug 
resistance cassette.  Flow cytometry analysis of Bcl11bYFP/+ mice either with or without the 
neomycin drug selection cassette [Bcl11b-YFP(+neo), Bcl11b-YFP(-neo)], together with non-
fluorescent controls (B6), using cells from the whole thymus (A), DN thymus (B), or the spleen 
(C). Bcl11b-YFP reporter expression is identical with or without the drug resistance cassette.  ISP 
– immature single positive, DP – double positive. 
 
 
 
Supplementary Fig. 4: Experimental and analysis workflow for time-lapse imaging of Bcl11b-
YFP levels in progenitor cells.  A) Experimental setup, microscope configuration and 
illumination settings used for timelapse image acquisition.  To confine cells to a single imaging 
field-of-view, progenitors were seeded into hollow PDMS microwells (Microsurfaces; 
Flemington, Australia) adhered to a glass-bottomed 24 well dish (Mattek; Ashland, MA).  B) 
Workflow for image analysis showing (I) raw differential interference contrast (DIC), mCherry 
and YFP images; (II) representative images overlaid with automatically segmented cell 
boundaries; and (III) heat maps showing cytometric analysis of segmented cells, showing OFF 
and ON populations. 
 
 
 
Supplementary Fig. 5: Notch signaling promotes all-or-none Bcl11b activation in a dose-
dependent manner.  Flow cytometry analysis of bone marrow derived Bcl11b-YFP- DN2 cells 
cultured under the indicated conditions with 5 ng/mL IL-7 and Flt3L for four days. CD25 versus 
Bcl11b-YFP levels (top), and histograms of Bcl11b-YFP and CellTrace Violet levels (bottom) are 
shown.  Initial levels (Day 0) are shown as gray dotted lines.  GSI: γ-secretase inhibitor 
(Calbiochem/EMD Millipore, Billerica, MA), a small molecule inhibitor of Notch signaling. 
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Supplementary Fig. 6: shTcf7 constructs reduce Tcf7 transcript levels in ETP and DN2 cells. 
Quantitative real time (RT)-PCR analysis of Tcf7 transcript levels in DN progenitors from E14.5 
fetal livers infected with the indicated shRNA constructs for 2 days and sorted.  RNA was 
extracted and processed as previously described7.   Forward and reverse primers used for Tcf7 
detection are CAAGGCAGAGAAGGAGGCTAAG and GGCAGCGCTCTCCTTGAG respectively, as 
previously described8. 
 
 
Supplementary Fig. 7: Effects of TCF-1 perturbation on Bcl11b activation in pro-T cells.  A) 
Flow cytometry analysis of bone marrow DN progenitors transduced with either shRNA to Tcf7 
(shTcf7) or a non-targeting control (shRandom), then cultured on plates coated with 6 µg/mL 
DL1 with 5 ng/mL SCF, IL-7 and Flt3L for four days.  Levels of the dendritic cell marker CD11c 
against FSC (top), as well as CD25 levels versus Bcl11b-YFP levels (middle) or Bcl11b-YFP level 
distributions (bottom) for CD11c- populations are shown.  Knockdown of Tcf7 promotes DC 
trans-differentiation in DN2 cells, but does not impede Bcl11b activation.  B) Flow cytometry 
analysis of Bcl11b-YFP expression levels in bone marrow DN progenitors transduced with a 
control or VEX-GFP retroviral construct for over-expression of TCF-1 (encoded by Tcf7), and 
cultured on OP9- or OP9-DL1 monolayers in 5 ng/mL IL-7 and Flt3L for three days.  TCF-1 over-
expression does not affect Bcl11b activation from either ETP or DN2 progenitors. 
 
Supplementary Fig. 8: Runx1, but not TCF-1 or GATA-3, controls Bcl11b expression amplitude 
in mature T cells.  A) Published transcriptomic data on Bcl11b expression in wildtype or Tcf7-/- 
DN3 thymocytes9 (left), or in wildtype or Gata3-/- Th2 cells10 (right).  Levels of Bcl11b expression 
are similar in the absence or presence of either factor. B) Flow cytometry analysis of CD4 and 
CD8 splenic T-cells activated with anti-TCRβ and anti-CD28 for 1 day, transduced with shRNA 
constructs, and cultured for 3 days.  Plots show CD8 versus CD3 for cells transduced with 
retrovirus (top), along with Bcl11b level distributions for gated non-CD8 T-cell populations 
(bottom).  Corresponding data for CD8 T-cells are shown in Fig. 8.  Solid black lines indicate cells 
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transduced with random shRNA, and dotted lines indicate background levels from non-
fluorescent T-cells.  Data from (A) represent mean and S.D. of two independent experiments.  
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SUPPLEMENTARY TABLES:   
 
Supplementary Table 1: Transcript levels for genes differentially expressed in Bcl11b-YFP- 
versus Bcl11b-YFP+ cells.  To compile this list, differential gene expression between two 
independent Bcl11b-YFP- and Bcl11b-YFP+ samples was evaluated, and a cutoff value of p < 
0.0005 was used.  FPKM values for different populations are shown, and p-values for 
differential expression across the indicated pairs of conditions are shown.  p-values were 
generated using the statistical model in the Cufflinks analysis software1.  Genes with a mean 
read count < 5 were not included in this analysis.  (separate Excel file) 
 
 
Supplementary Table 2:  Transcript levels for transcriptional regulators expressed in 
developing T-cells.  FPKM values for different populations are shown, and p-values for 
differential expression across the indicated pairs of conditions are shown.  p-values were 
generated using the statistical model in the Cufflinks analysis software1.  Genes with a mean 
read count < 5 were not included in this analysis.  A) Transcript levels for selected T-cell 
regulatory genes from RNA-Seq analysis. B) Transcript levels for all expressed genes classified as 
transcription regulators from gene ontology (GO:0006355) from RNA-Seq analysis.  
Interestingly, although the key transcription factor gene Lef1 is turned on shortly after Bcl11b, it 
is not significantly upregulated yet in the stages analyzed here.  (separate Excel file) 
 
Supplementary Table 3: List of vectors used for this study.  Underlined sequences indicate 
shRNA loop sequences. References to supplementary figures are designated as Fig. S(number). 
 
Supplementary Table 4:  Antibodies used for this study.  All reagents were obtained from 
eBioscience (San Diego, USA), unless otherwise indicated. References to supplementary figures 
are designated as Fig. S(number). 
 
 
Supplementary Tables 1 and 2:  See separate Excel files. 
Supplementary Tables 3 and 4 are below 
SUPPLEMENTARY REFERENCES FOLLOW SUPPLEMENTARY TABLE 4 
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SUPPLEMENTARY TABLE 3: List of vectors used for this study 
Vector name Notes / sequence Usage 
Bcl11b-3’UTR-YFP-BAC Modified BAC containing YFP 
reporter inserted into Bcl11b 3’UTR 
 
Generation of Bcl11b 
3’UTR targeting vector 
Bcl11b-YFP 3’UTR targeting 
vector  
Gene targeting vector  ES cell gene targeting 
Banshee shRandom-mCherry CCTAGGGTTAGGTCGCCCTC
GTTCAAGAGACGAGGGCGAC
TTAACCTTAGG 
 
Control for shRNA 
knockdown (Fig. 7, 8) 
Banshee shTcf7-v1 mCherry 
 
GCCACGAGTCTGAACAATAAT
 TTCAAGAGAATTATTGTTTAG
ACTTGTGGC 
Tcf7 knockdown in T-cell 
progenitors (Fig. 7) 
Banshee shTcf7-v2 mCherry 
 
CAATGTGTTCATGCTTTGCAT 
TTCAAGAGAATGTAAAGCATG
AACGCATTG 
Tcf7 knockdown in T-cell 
progenitors (Fig. 7) 
Banshee shGata3 mCherry GAAGTTCAGTGTCCGCTGACGTTCGT
AGCCGTCAGCGGATACTGAGCTTC, 
from2 
 
Gata3 knockdown in T-
cell progenitors (Fig. 7) 
Banshee shRunx1 mCherry GTCTTTGCAAATTCACCACAATTCAA
GAGATTGTGGCGGATTTGTAAAGAC 
Runx1 knockdown in T-
cell progenitors (Fig. 8) 
MSCV Runx1-IRES-mCherry  Runx1 over-expression in 
T-cell progenitors (Fig. 8) 
MSCV RunxDN-IRES-mCherry  Runx protein inhibition in 
T-cell progenitors (Fig. 8) 
MSCV IRES-mCherry (empty 
vector) 
From3 Control for protein over-
expression experiments 
(Fig. 8) 
MSCV H2B-mCherry-IRES-ngfr  Nuclear-localized 
fluorescence signal for 
automated cell tracking 
(Fig. 5) 
MSCV VEX From4 Control for TCF-1 over-
expression experiments 
(Fig. S7) 
MSCV TCF-1 VEX From4 TCF-1 over-expression 
experiments (Fig. S7) 
 
Supplementary Table 3: Underlined sequences indicate shRNA loop sequences. 
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SUPPLEMENTARY TABLE 4: Antibodies used for this study 
 Antibody 
epitope/conjugate 
Clone Dilution/ 
Concentration 
Usage 
CD44 eFluor-450 1M7 1:300 DN thymocyte analysis (Figs. 1, S3) 
Cultured DN progenitors (Figs. 1, 7, S7) 
Sorting of DN progenitors (Figs. 2-7) 
 
CD117 (cKit) PE 2B8 1:150 DN thymocyte analysis (Figs. 1, S3) 
Sorting of DN progenitors (Figs. 2-7) 
Cultured DN progenitors (Fig. 3) 
CD25 APC-eFluor780 PC61.5 
 
1:300 DN thymocyte analysis (Figs. 1, S3) 
CD4+CD25+ T-reg analysis (Fig. 1) 
Cultured DN progenitors (Fig. 1, 3, 4, 8, 
S5, S7) 
Sorting of DN progenitors (Figs. 2-7) 
 
CD4 PE GK1.5 1:300 CD4 SP thymocyte analysis (Figs. 1, S3)  
CD8α APC 53-6.7 1:300 CD8 SP thymocyte analysis (Figs. 1, S3) 
CD24 (HSA) eFluor-450 M1/69 1:400 Analysis of ISP thymocytes (Figs. 1, S3) 
CD19 eFluor-450 1D3 1:300 Analysis of B-cells (Figs. 1, S3) 
TCR γδ APC GL3 1:300 γδT-cell analysis (Fig. 1) 
NK1.1 PE PK136 1:300 NK, NKT cell analysis (Fig. 1) 
TCRβ eFluor-450 H57-197 1:300 NKT cell analysis (Fig. 1) 
CD45 APC 30-F11 1:300 Cultured DN progenitors (Fig. 1, 3) 
Sorting of DN progenitors (Figs. 2-7) 
CD11c APC-e780 N418 1:300 Alternate lineage potential assays 
(Fig. 2, limiting dilution assays) 
CD11c e450 N418 1:300 Alternate lineage potential assays 
(Fig 2, 300 cell assay; Fig. S7) 
DX5 (CD49B) APC DX5 1:300 Alternate lineage potential assays 
(Fig. 2, 300 cell assay) 
NK1.1 APC PK136 1:300 Alternate lineage potential assays 
(Fig. 2) 
CD45 eFluor-450 30-F11 1:300 Alternate lineage potential assays (Fig. 
2) 
CD11c eFluor-450 N418 1:300 Cultured DN progenitors (Fig. 6) 
CD25 Brilliant Violet-
510 (Biolegend) 
PC61 1:300 Cultured DN progenitors (Fig. 7) 
CellTrace Violet 
(Invitrogen) 
 5 µM Cultured DN progenitors (Fig. 4, Fig. S5) 
CD8a biotin 53-6.7 1:150 Thymocyte depletion (Fig. 1, S3) 
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Supplementary Table 4:  All reagents were obtained from eBioscience (San Diego, USA), unless 
otherwise indicated. 
Splenic T-cell enrichment (Fig. 8, S8) 
 
TCRγδ biotin GL3 1:100 Thymocyte depletion (Fig. 1, S3) 
TCRβ biotin H57-597 1:150 Thymocyte depletion (Fig. 1, S3) 
Gr-1 Ly6D biotin R86.8C5 1:100 Thymocyte depletion (Fig. 1, S3) 
TER-119 biotin Ter119 1:100 
1:100 
Thymocyte depletion (Fig. 1, S3) 
Bone marrow depletion (Figs. 2-7, S5, 
S7) 
CD122 biotin 5H4 1:100 
 
Thymocyte depletion (Fig. 1, S3) 
NK1.1 biotin PK136 1:100 Thymocyte depletion (Fig. 1, S3) 
Bone marrow depletion (Figs. 2-7, S5, 
S7) 
CD11c biotin N418  
1:100 
Thymocyte depletion (Fig. 1, S2) 
Bone marrow depletion (Figs. 2-7, S5, 
S7) 
CD11b biotin M1/70 1:100 Bone Marrow depletion (Figs. 2-7, S5, 
S7) 
CD19 biotin 
(Biolegend) 
6D5 1:100 Bone Marrow depletion (Figs. 2-7, S5, 
S7) 
CD3 biotin (Biolegend) 145-2C11 1:100 Bone Marrow depletion (Figs. 2-7, S5, 
S7) 
Streptavidin PerCP-
Cy5.5 
 1:100 Sorting of DN progenitors (Figs. 2-7) 
CD4 biotin GK1.5 1:100 Splenic T-cell enrichment (Fig. 8, S8) 
TCRβ (Biolegend) H57-597 1 µg/mL 
coating 
CD8 T-cell activation (Figs. 8, S8) 
CD28 (Biolegend) 37.51 1 µg/mL CD8 T-cell activation (Figs. 8, S8) 
CD8a e450 53-6.7 1:300 CD8 T-cell activation (Figs. 8, S8) 
CD3 APC-e780 17A2 1:300 CD8 T-cell activation (Figs. 8, S8) 
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